Articles tagged with: IMGN901

News»

[ by | Jan 4, 2013 3:54 pm | Comments Off ]
Lorvotuzumab Mertansine Combination Effective In Relapsed/Refractory Multiple Myeloma Patients (ASH 2012)

Results from an ongoing Phase 1 study demonstrate that lorvotuzumab mertansine in combination with Revlimid and dexamethasone is effective as a therapy for relapsed and refractory myeloma patients.

The updated trial results were presented by Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, the American Society of Hematology (ASH) annual meeting in Atlanta last month.

Ten patients are currently continuing with the clinical trial. According to Dr. Berdeja, these interim results support the continued evaluation of the combination in relapsed and refractory myeloma patients. "This was a fairly …

Read the full story »

News»

[ by | Updated: Jan 4, 2013 4:20 pm | 2 Comments ]
ASH 2012 Multiple Myeloma Update – Day Three: Late Afternoon Oral Session

This year’s American Society of Hematology (ASH) meeting, which is taking place in Atlanta, came to a close earlier today.  However, yesterday, the third day of the meeting, was packed with myeloma-related presentations.

Given the number of myeloma presentations made yesterday, The Beacon will summarize the four most important of yesterday’s oral presentation sessions as well as a number of the most important poster presentations in updates such as this one.  Summaries of the first three key oral presentation sessions were published yesterday and earlier today.  This update covers presentations from the …

Read the full story »

News»

[ by | Nov 19, 2012 1:03 pm | 5 Comments ]
New Multiple Myeloma Treatments On The Horizon (ASH 2012)

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …

Read the full story »

News»

[ by | Sep 26, 2012 11:37 am | Comments Off ]
New Agents In Combination With Revlimid Show Promise For Relapsed / Refractory Multiple Myeloma

Treatment strategies that com­bine Revlimid with newer types of anti-tumor agents may be ef­fec­tive for re­lapsed and re­frac­tory mul­ti­ple myeloma, ac­cord­ing to myeloma experts who reviewed re­­sults from stud­ies of these new com­bi­na­tions.

Refractory and re­lapsed mul­ti­ple myeloma is notoriously dif­fi­cult to treat. For every remission period that is achieved, relapse typ­i­cally arises sooner and with greater re­sis­tance to pre­vi­ously used ther­a­pies. These patients have lim­ited op­tions for ther­apy.

In examining trials that tested new ther­a­pies in com­bi­na­tion with Revlimid (lena­lido­mide), the authors of the review hoped to find the po­ten­tial …

Read the full story »

News»

[ by and | Jun 7, 2011 11:55 am | Comments Off ]
Lorvotuzumab Mertansine Combination Shows Activity In Myeloma (ASCO 2011)

Results of an ongoing Phase 1 clinical trial indicate that the anti-cancer drug lorvotuzumab mertansine in combination with Revlimid-dexamethasone is active in relapsed/refractory multiple myeloma patients.

“There is encouraging activity observed at all dose levels,” said Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, who presented these findings at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

In a summary talk about potential new myeloma treatments, Dr. Nikhil Munshi from the Dana-Farber Cancer Institute said that he was encouraged by these first …

Read the full story »

News»

[ by | Jun 6, 2011 9:02 am | 2 Comments ]
ASCO 2011 Multiple Myeloma Update - Day Three, Part One

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

There was a morn­ing session where a total of eight re­search abstracts were pre­sented and discussed.  Then, late in the afternoon, there was an education session focused on mul­ti­ple myeloma, with sev­er­al dif­fer­en­t pre­sen­ta­tions.

The pre­sen­ta­tions during the morn­ing session were on three dif­fer­en­t topics: Revlimid (lena­lido­mide) and its po­ten­tial link to sec­ond­ary cancer; myeloma bone dis­ease; and new drugs being devel­oped as po­ten­tial …

Read the full story »

News»

[ by and | May 25, 2011 6:26 pm | One Comment ]
Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 47th Annual Meeting (ASCO 2011)

The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago.

More than 30,000 clin­i­cal spe­cialists from all over the world are ex­pected to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. This year’s meeting will primarily focus on the theme of “Patients, Pathways, Progress.”

The meeting will in­clude many pre­sen­ta­tions and seminars focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists over 40 myeloma-based abstracts.

The Myeloma Beacon will be …

Read the full story »